OmniAb's Lilly Deal Validates Platform and Improves Cash Runway, but Revenue Conversion Remains Key

What happened

OmniAb announced a collaboration with Eli Lilly, which serves as a strong validation of its antibody discovery technology and has attracted attention from other large pharma partners. The deal has increased OmniAb's partner count to 110 and active programs to 425, with a disclosed clinical-stage milestone pool of $340 million and a total milestone pool exceeding $3 billion. As a result, management has raised its 2026 cash guidance from the prior $30–35 million to a range of $49–53 million, signaling improved near-term liquidity and reduced dilution risk. However, revenue remains highly variable because OmniAb's economics are tied to partner milestone achievements, which are outside the company's control, and the previous base business of services and licenses remains small. The critical next step is whether the Lilly deal and other partnerships convert into actual milestone payments and royalty streams, as the company has historically struggled to translate partner growth into consistent revenue.

Implication

The Lilly collaboration is a tangible endorsement that could attract additional partners and increase the probability of future milestone payments, supporting a re-rating of the stock if the partnership pipeline continues to expand. The improved cash guidance of $49–53 million extends the runway, lowering the likelihood of near-term equity dilution and giving management more time to execute on xPloration and other recurring revenue initiatives. However, investors should remain cautious because the core business has yet to demonstrate that its large number of partners and programs will generate predictable and growing revenue; FY2025 revenue actually declined from the prior year. The next few quarters will be critical: if OmniAb reports additional xPloration instrument placements or partner-driven milestone payments, the upside case strengthens; if not, the stock may remain range-bound. Therefore, while the risk-reward has improved, we would wait for signs of actual revenue acceleration before establishing a full position, and current shareholders may use strength to trim if the stock approaches prior resistance levels.

Thesis delta

The thesis has shifted from a cautious wait to a more constructive stance due to the Eli Lilly deal and improved cash guidance, which reduce near-term dilution risk and validate the platform. However, the fundamental challenge of converting partner breadth into consistent revenue remains unchanged, and we still need to see xPloration scale or milestone payments materialize. As such, the rating moves from WAIT to a slightly more positive WAIT/ACCUMULATE on weakness, but not yet a BUY.